$1.67 Billion is the total value of Frazier Life Sciences Management, L.P.'s 48 reported holdings in Q2 2023. The portfolio turnover from Q1 2023 to Q2 2023 was 33.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PHAT | Buy | PHATHOM PHARMACEUTICALS INC | $144,764,875 | +141.2% | 10,109,279 | +20.2% | 8.64% | +98.9% |
| Buy | NEWAMSTERDAM PHARMA COMPANYordinary shares | $129,265,738 | +3.0% | 10,871,803 | +16.4% | 7.72% | -15.1% | |
| KRYS | Buy | KRYSTAL BIOTECH INC | $116,256,524 | +53.6% | 990,260 | +4.7% | 6.94% | +26.7% |
| MIRM | Buy | MIRUM PHARMACEUTICALS INC | $112,795,968 | +21.7% | 4,360,107 | +13.0% | 6.74% | +0.3% |
| RYTM | Buy | RHYTHM PHARMACEUTICALS INC | $35,737,491 | -7.5% | 2,167,222 | +0.1% | 2.13% | -23.7% |
| BBIO | Buy | BRIDGEBIO PHARMA INC | $34,208,667 | +76.1% | 1,988,876 | +69.8% | 2.04% | +45.2% |
| New | DISC MEDICINE INC | $29,082,000 | – | 655,000 | +100.0% | 1.74% | – | |
| AVTE | Buy | AEROVATE THERAPEUTICS INC | $17,061,815 | +150.2% | 994,858 | +194.2% | 1.02% | +106.3% |
| ORIC | New | ORIC PHARMACEUTICALS INC | $16,628,555 | – | 2,142,855 | +100.0% | 0.99% | – |
| TRVI | Buy | TREVI THERAPEUTICS INC | $16,445,805 | +33.4% | 6,881,090 | +3.3% | 0.98% | +10.0% |
| MORF | Buy | MORPHIC HLDG INC | $15,221,746 | +88.8% | 265,511 | +23.9% | 0.91% | +55.7% |
| RETA | New | REATA PHARMACEUTICALS INCcl a | $10,239,843 | – | 100,430 | +100.0% | 0.61% | – |
| MGNX | Buy | MACROGENICS INC | $9,647,141 | -21.0% | 1,803,204 | +5.9% | 0.58% | -34.8% |
| EWTX | Buy | EDGEWISE THERAPEUTICS INC | $5,804,921 | +27.5% | 749,022 | +9.8% | 0.35% | +5.2% |
| BLUE | Buy | BLUEBIRD BIO INC | $5,625,594 | +22.8% | 1,709,907 | +18.7% | 0.34% | +1.2% |
| DCPH | New | DECIPHERA PHARMACEUTICALS IN | $5,209,600 | – | 370,000 | +100.0% | 0.31% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-08-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ARCUTIS BIOTHERAPEUTICS INC | 7 | Q3 2023 | 17.0% |
| MIRUM PHARMACEUTICALS INC | 7 | Q3 2023 | 13.6% |
| PHATHOM PHARMACEUTICALS INC | 7 | Q3 2023 | 8.6% |
| KRYSTAL BIOTECH INC | 7 | Q3 2023 | 7.6% |
| SYNDAX PHARMACEUTICALS INC | 7 | Q3 2023 | 6.3% |
| VAXCYTE INC | 7 | Q3 2023 | 4.8% |
| CRINETICS PHARMACEUTICALS IN | 7 | Q3 2023 | 3.1% |
| ALPINE IMMUNE SCIENCES INC | 7 | Q3 2023 | 3.2% |
| TARSUS PHARMACEUTICALS INC | 7 | Q3 2023 | 2.5% |
| KALVISTA PHARMACEUTICALS INC | 7 | Q3 2023 | 2.1% |
View Frazier Life Sciences Management, L.P.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR/A | 2023-02-07 |
| 13F-HR | 2023-02-03 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-10 |
| 13F-HR | 2022-05-16 |
View Frazier Life Sciences Management, L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.